SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 261,202 call options on the company. This represents an increase of approximately 522% compared to the average volume of 42,008 call options.
SELLAS Life Sciences Group Trading Up 156.4%
SLS stock traded up $11.68 during mid-day trading on Tuesday, hitting $19.15. 118,919,137 shares of the company were exchanged, compared to its average volume of 8,361,787. The firm has a fifty day simple moving average of $10.90 and a 200 day simple moving average of $8.79. The company has a market capitalization of $3.87 billion, a PE ratio of -95.75 and a beta of 2.73. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $24.89.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on SELLAS Life Sciences Group
More SELLAS Life Sciences Group News
Here’s some of the latest news about SLS:
- Positive Sentiment: SELLAS plans to meet with the FDA to discuss the regulatory path, including a possible accelerated filing strategy, and is preparing for a Biologics License Application submission in the first half of 2027. GPS was generally well tolerated, with no new safety signals reported.
- Positive Sentiment: Options trading was unusually active, with investors buying 261,202 call options—about 522% above the average volume. This suggests heightened bullish speculation, but options activity does not guarantee future performance.
- Negative Sentiment: The results are topline data; comprehensive analyses of secondary endpoints are still underway. FDA agreement on the data, filing strategy, timing, and eventual approval is not assured. The trial studied a specific high-risk AML population, so the findings may not apply broadly.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Dagco Inc. increased its holdings in shares of SELLAS Life Sciences Group by 8.4% in the 3rd quarter. Dagco Inc. now owns 1,336,449 shares of the company’s stock valued at $16,452,000 after acquiring an additional 104,016 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in SELLAS Life Sciences Group by 86.0% in the third quarter. Goldman Sachs Group Inc. now owns 1,088,136 shares of the company’s stock worth $13,395,000 after purchasing an additional 503,101 shares during the period. Bank of America Corp DE boosted its holdings in SELLAS Life Sciences Group by 535.7% in the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after purchasing an additional 540,748 shares during the period. Wellington Management Group LLP boosted its holdings in SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock worth $8,816,000 after purchasing an additional 252,531 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in SELLAS Life Sciences Group during the second quarter valued at $7,823,000. Institutional investors own 17.38% of the company’s stock.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Stories
- Five stocks we like better than SELLAS Life Sciences Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
